Neo-adjuvant and adjuvant chemotherapy of gastric cancer
Open Access
- 1 June 2007
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 18 (suppl_6) , vi120-vi123
Abstract
Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgery is the primary curative treatment of locoregional gastric cancer. In Western countries, however, at the time of resection, most patients are expected to have regional lymph node involvement with poor prognostic implications. To improve these results, different trials have been carried out in the adjuvant or neo-adjuvant setting. Many phase III trials of adjuvant therapy have been conducted; however, postoperative treatment modalities have not proven to be superior to postsurgical observation alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed. On the contrary, neo-adjuvant chemotherapy has shown promising results as suggested by the final results of UK Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial.Keywords
This publication has 26 references indexed in Scilit:
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trialEuropean Journal of Surgical Oncology, 2004
- Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group TrialJournal of Clinical Oncology, 2004
- Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960International Journal of Cancer, 2004
- Monitoring falls in gastric cancer mortality in EuropeAnnals of Oncology, 2004
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Extended Lymph-Node Dissection for Gastric CancerNew England Journal of Medicine, 1999
- Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patientsThe Lancet, 1995
- Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275)Cancer, 1985